Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. DISCOVERY AND DEVELOPMENT COLLABORATION AND LICENSE AGREEMENT by and between AGIOS PHARMACEUTICALS, INC. and CELGENE...Discovery and Development Collaboration and License Agreement • July 16th, 2013 • Agios Pharmaceuticals Inc • Pharmaceutical preparations • New York
This Discovery and Development Collaboration and License Agreement (this “Agreement”) is entered into as of April 14, 2010 (the “Effective Date”), by and between Agios Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware and having its principal office at 38 Sidney St., 2nd Floor, Cambridge, MA 02139-4169 (“Agios”), and Celgene Corporation, a corporation organized and existing under the laws of the State of Delaware and having its principal office at 86 Morris Avenue, Summit, NJ 07901 (“Celgene”).
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. [****] denotes omissions. THIRD AMENDMENT TO DISCOVERY AND DEVELOPMENT COLLABORATION AND LICENSE AGREEMENTDiscovery and Development Collaboration and License Agreement • February 24th, 2015 • Agios Pharmaceuticals Inc • Pharmaceutical preparations
This Third Amendment to the Discovery and Development Collaboration and License Agreement (the “Third Amendment”) is entered into as of July 14th, 2014 (the “Third Amendment Effective Date”) by and between Agios Pharmaceuticals, Inc. (“Agios”) and Celgene Corporation (“Celgene”). Agios and Celgene may each be referred to herein individually as a “Party” and collectively as the “Parties.” Capitalized terms used in this Third Amendment and not otherwise defined herein shall have the meanings set forth in the Agreement. All references to Sections and Articles herein are references to Sections and Articles of the Agreement.
